Effect of Sangu Decoction (三骨汤) on metastatic bone destruction in rats with mammary cancer

Bo Deng; Li-qun Jia; Fu-yun Gao; Jian Cui; Huan Li

doi:10.1007/s11655-011-0802-3

Your Location：

Home >

Browse articles >

Effect of Sangu Decoction (三骨汤) on metastatic bone destruction in rats with mammary cancer

Updated：2021-08-27

- Effect of Sangu Decoction (三骨汤) on metastatic bone destruction in rats with mammary cancer
- Chinese Journal of Integrative Medicine Vol. 18, Issue 4, Pages: 304-307(2012)
- Affiliations：
  
  1. Department of Chinese Medicine on Tumor, China-Japan Friendship Hospital,Beijing,China
  2. Beijing University of Chinese Medicine,Beijing,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-011-0802-3
  CLC：
- Published：2012，
  
  Published Online：30 March 2012，
Scan for full text
Deng, B., Jia, Lq., Gao, Fy. et al. Effect of Sangu Decoction (三骨汤) on metastatic bone destruction in rats with mammary cancer., Chin. J. Integr. Med. 18, 304–307 (2012). https://doi.org/10.1007/s11655-011-0802-3

Bo Deng, Li-qun Jia, Fu-yun Gao, et al. Effect of Sangu Decoction (三骨汤) on metastatic bone destruction in rats with mammary cancer. [J]. Chinese Journal of Integrative Medicine 18(4):304-307(2012)
Deng, B., Jia, Lq., Gao, Fy. et al. Effect of Sangu Decoction (三骨汤) on metastatic bone destruction in rats with mammary cancer., Chin. J. Integr. Med. 18, 304–307 (2012). https://doi.org/10.1007/s11655-011-0802-3 DOI：

Bo Deng, Li-qun Jia, Fu-yun Gao, et al. Effect of Sangu Decoction (三骨汤) on metastatic bone destruction in rats with mammary cancer. [J]. Chinese Journal of Integrative Medicine 18(4):304-307(2012) DOI： 10.1007/s11655-011-0802-3.

摘要

To study and evaluate the effect of Sangu Decoction (SGD

三骨汤) on the bone destruction due to mammary cancer metastasis. Metastasis rat mammary tumor-1 cells were transplanted into the left hind limb tibia of SD rats to establish the bone metastasis of the mammary cancer model. The modeled rats were treated with SGD for observing its effect on rats’ pain behavior

including 50% paw withdrawal threshold (50% PWT) after von Frey fiber stimulation

burden difference of bilateral feet

and thermal withdrawal latency (TWL)

with zoledronic acid as the positive control. Moreover

the damage in the tibia sample of rats was scored by an iconographic method

and the bone mineral density (BMD) as well as the bone mineral content (BMC) were estimated. The model established showed characteristics of mixed metastasis

revealing the manifestations of tumor development

bone destruction

cancerous pain

etc. In the SGD-treated group

50% PWT was prolonged (8.13±4.76 vs. 2.30±2.19)

and TWL was longer (3.48±0.62 s vs. 2.89±0.26 s) than those in the control group

respectively (P<0.05 or P<0.01). Iconographic scoring also showed improvement of BMD (0.134±0.009 vs. 0.120±0.007

P<0.01) and an elevating trend of BMC in the SGD-treated group. SGD could effectively alleviate the cancerous pain of bone metastasis and mitigate the metastasis that cause osteolytic destruction of bone.

Abstract

To study and evaluate the effect of Sangu Decoction (SGD

including 50% paw withdrawal threshold (50% PWT) after von Frey fiber stimulation

burden difference of bilateral feet

and thermal withdrawal latency (TWL)

with zoledronic acid as the positive control. Moreover

the damage in the tibia sample of rats was scored by an iconographic method

and the bone mineral density (BMD) as well as the bone mineral content (BMC) were estimated. The model established showed characteristics of mixed metastasis

revealing the manifestations of tumor development

bone destruction

cancerous pain

etc. In the SGD-treated group

50% PWT was prolonged (8.13±4.76 vs. 2.30±2.19)

and TWL was longer (3.48±0.62 s vs. 2.89±0.26 s) than those in the control group

respectively (P<0.05 or P<0.01). Iconographic scoring also showed improvement of BMD (0.134±0.009 vs. 0.120±0.007

关键词

cancerous painmetastasis of mammary cancerChinese medicine therapybone destruction

Keywords

cancerous painmetastasis of mammary cancerChinese medicine therapybone destruction

references

Cazzaniga ME, Dogliotti L, Cascinu S, Barni S, Labianca R, Chiara S, et al. Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study. Oncology 2006;71:374–381.

Peng H, Sohara Y, Moats RA, Nelson Jr MD, Groshen SG, Ye W, et al. The activity of zoledronic acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. Cancer Res 2007;67:9346–9355.

Clohisy DR, Mantyh PW. Bone cancer pain. Cancer 2003;97(3 Suppl):866–873.

Medhurst SJ, Walker K, Bowes M, Kidd BL, Glatt M, Muller M, et al. A rat model of bone cancer pain. Pain 2002;96:129–140.

Walker K, Medhurst SJ, Kidd BL, Glatt M, Bowes M, Patel S, et al. Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. Pain 2002;100:219–229.

Tsagozis P, Eriksson F, Pisa P. Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages. Cancer Immunol Immunother 2008;57:1451–1459.

Roudier MP, Bain SD, Dougall WC. Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats. Clin Exp Metastasis 2006;23:167–175.

Gouin F, Ory B, Rédini F, Heymann D. Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. Int J Cancer 2006;119:980–984.

Ogawa K, Mukai T, Asano D, Kawashima H, Kinuya S, Shiba K, et al. Therapeutic effects of a 186Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model. J Nucl Med 2007;48:122–127.

Journé F, Kheddoumi N, Chaboteaux C, Duvillier H, Laurent G, Body JJ. Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells. Breast Cancer Res 2008;10:R4.

FULL TEXT LINK

More>

Views

776

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Application of Response Evaluation Criteria of Traditional Chinese Medicine for Solid Tumor in advanced non-small cell lung cancer

A one-year evaluation of radiographic progression in patients with rheumatoid arthritis treated by Qingre Huoxue Decoction (清热活血方)

Alleviation of cancerous pain by external compress with Xiaozheng Zhitong Paste (消癥止痛方)

Assessment of the clinical effect of Chinese medicine therapy combined with psychological intervention for treatment of patients of peri-menopausal syndrome complicated with hyperlipidemia

A multicenter, randomized, double-blind clinical study on Wufuxinnaoqing Soft Capsule (五福心脑清胶囊) in treatment of chronic stable angina patients with blood stasis syndrome

Related Author

No data

Related Institution

Department of Oncology, First Affiliated Hospital of Guangzhou University of Chinese Medicine

Guangzhou University of Chinese Medicine

Department of Radiology, Beijing Union Hospital

Department of Radiology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences

Department of Rheumatology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰